Please ensure Javascript is enabled for purposes of website accessibility

Why Momenta Pharmaceuticals Fell 12.6% Today

By Todd Campbell - Nov 1, 2017 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A disappointing third-quarter performance and bad news for its biosimilars took a toll on the company's shares today.

What happened

After the company reported third-quarter financials and updated investors on the progress of its biosimilars pipeline, shares of Momenta Pharmaceuticals (MNTA) lost 12.6% of their value earlier today.

So what

Momenta Pharmaceuticals recorded $10.9 million in product revenue from sales of it and Sandoz's Glatopa 20 mg, a sharp decline from the $23.3 million reported in Q3 2016. Glatopa is a biosimilar to 20 mg Copaxone, a blockbuster multiple sclerosis drug.

A man holds his head in his hands as he stands in front of a chart showing a declining share price.


The 53% decrease in Glatopa revenues was due mostly to price discounts associated with Medicaid and inventory price adjustments tied to the FDA's approval of Mylan's (MYL) 20 mg and 40 mg Copaxone biosimilar in early October. Additionally, a $10 million commercial milestone payment made by Sandoz to Momenta was subtracted from Glatopa's net profit prior to calculating Momenta's 50% share of Glatopa's profit. 

The company also updated investors on its pipeline progress. It's still awaiting a decision from the FDA on its 40 mg long-lasting Copaxone, but it hopes to hear from the regulator either this quarter or early in 2018. 

It plans on submitting its Humira biosimilar for approval soon; however, it conceded in its press release that it doesn't expect Humira biosimilars to launch in the U.S. until 2022 because of Humira patents. Momenta Pharmaceuticals and other biosimilar drugmakers have been litigating for a faster launch schedule, but this admission suggests that's less likely.

Additionally, the company reported that a collaboration with Mylan on a biosimilar to Orencia hit a roadblock. Their formulation failed to meet its primary pharmacokinetic endpoints in a Phase 1 study, an event that will cause development delays. 

Now what

Momenta Pharmaceuticals revenue could continue lower until the FDA approves its 40 mg Copaxone. The 40 mg variation has become much more widely prescribed than the 20 mg version, and that trend is going to accelerate now that Mylan has a 40 mg formulation on the market. 

The Humira hiccup is disappointing because Humira is the world's best-selling drug with $18 billion in annual sales. Ultimately, a launch will open up a big market for Momenta Pharmaceuticals, but it could be years before that materializes in the U.S.

As for Orencia, Mylan and Momenta Pharmaceuticals plan to study the data to determine where they went wrong. The two companies have plenty of resources to get this program back on track, but again, it could take some time.

Overall, Momenta Pharmaceuticals' GAAP operating expenses of $58.6 million in the third quarter significantly exceeded the company's $24 million in profit-sharing and milestones, so investors should expect losses to continue as the company continues to spend heavily on biosimilars R&D. 


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Momenta Pharmaceuticals, Inc. Stock Quote
Momenta Pharmaceuticals, Inc.
Viatris Inc. Stock Quote
Viatris Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.